Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Cash flows from operating activities:
Net loss	$ (32,548,215)	$ (2,628,555)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	195,399	224,574
Stock-based compensation	734,928	194,190
Income taxes		39,105
Foreign currency losses (gains)	66,132	(118,697)
Provision for credit losses		495,000
Noncash provision for excess inventory	771,580	292,405
Changes in other non-cash items	184	200,000
Changes in assets and liabilities:
Accounts receivable	3,082,659	(420,919)
Contract assets and unbilled receivables	(2,177,260)	934,759
Inventory	694,949	(665,589)
Prepaid expenses, other current assets and other assets	(366,540)	(525,705)
Accounts payable and accrued expenses	1,682,980	(1,983,304)
Contract liabilities and billings in excess of revenue earned	(43,746)	(211,815)
Accrued litigation damages	24,800,000
Net cash used in operating activities	(3,106,950)	(4,174,551)	$ (15,300,000)
Cash flows from investing activities:
Capital expenditures	(245,429)	(216,618)
Purchases of marketable debt securities	(230,012)	(17,624,779)
Proceeds from sale of marketable debt securities	5,000,060	1,000,000
Other assets		1,000
Net cash from (used in) investing activities	4,524,619	(16,840,397)
Cash flows from financing activities:
Issuance of common stock, net of costs	7,242,581
Issuance of common stock and pre-funded warrants, net of costs		21,335,000
Net cash provided by financing activities	7,242,581	21,335,000
Effect of exchange rate changes on cash	(2,173)	4,216
Net increase in cash, cash equivalents and restricted cash	8,658,077	324,268
Cash, cash equivalents and restricted cash:
Beginning of period	6,210,685	8,258,878	8,258,878
End of period	$ 14,868,762	$ 8,583,146	$ 6,210,685